LTS Lohmann Therapie Systeme AG, market leader in medical patches, Transdermal Therapeutic Systems (TTS) and Oral Thin Films (OTF) announced the appointment of Prof. Dr. Wolfgang Hartwig as new Chairman of the Executive Board as of January 1st, 2012. He succeeds Dr. Hans-Rainer Hoffmann who retired as of December 31st, 2011.
Professor Dr. Wolfgang Hartwig has held various top-management positions within the Bayer AG for several years including President and CEO of the Diagnostic Division of Bayer Healthcare and Head of Global Pharma Research and Development. He was also member of the Bayer Healthcare Executive Committee.
Supervisory board chairman Prof. Dr. Norbert Loos: “On behalf of the entire Supervisory Board I would like to thank Dr. Hans-Rainer Hoffmann, founder of this company, for the successful work in leading this company during the past years and I would like to wish him all the best for his future. We are very pleased to be able to appoint with Prof. Hartwig an internationally experienced expert and distinguished leader in the area of pharmaceuticals to serve as the company’s new chairman of the executive board. We are convinced that he will inspire the innovative growth of the LTS group.”
Prof. Dr. Wolfgang Hartwig: ”I am looking forward to my new challenging role. I am impressed by what LTS has accomplished with respect to the development and production of Transdermal Systems and Oral Thin Films and I am confident that LTS will further strengthen its market leader position with new innovative technologies.”
Simultaneously, Sebastian Schäfer, currently CEO of the LTS subsidiary in West Caldwell, NJ, USA, has been appointed as member of the Executive Board.
LTS is world leading in the development and production of Transdermal Systems and Oral Thin Film Systems. The products developed by LTS comprise a multitude of innovations, including the world-wide first nicotine patch as well as the only patch against Parkinson’s and Restless-Legs-Syndrome. This is also the first medication in the world which was developed as a patch formulation right from the very beginning.
The innovative capacity of LTS in the market for Oral Thin Films resulted in the launch of Listerine® Pocketpacks® that now dominate the North American market. Over one Billion strips have been produced by LTS Corp during the first three years after market launch.
More than 5000 patents underpin the company’s leading position in the development of such technologies. Additionally, since the late 1990´s LTS has been majority shareholder of the “CRS Clinical Research Services” that perform clinical trials in early stages. By that LTS offers its customers the entire range of services: from the development of new formulations and clinical trials to manufacturing and final packaging.